The new data suggests that the GMP production of exosomes can be successfully scaled up using traditional bioreactor technology. This represents an important step in establishing the utility of ReNeuron’s exosome technology as a drug delivery platform for biologics and/or nucleotides for gene therapy. We look forward to further updates with interest.
31 Jan 2019
Supportive manufacturing data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Supportive manufacturing data
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
31 Jan 2019 -
Author:
Dr Jens Lindqvist -
Pages:
3
The new data suggests that the GMP production of exosomes can be successfully scaled up using traditional bioreactor technology. This represents an important step in establishing the utility of ReNeuron’s exosome technology as a drug delivery platform for biologics and/or nucleotides for gene therapy. We look forward to further updates with interest.